Thomas Agnew

575 total citations
10 papers, 335 citations indexed

About

Thomas Agnew is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Thomas Agnew has authored 10 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Cellular and Molecular Neuroscience. Recurrent topics in Thomas Agnew's work include PARP inhibition in cancer therapy (5 papers), Mitochondrial Function and Pathology (3 papers) and Genetic Neurodegenerative Diseases (3 papers). Thomas Agnew is often cited by papers focused on PARP inhibition in cancer therapy (5 papers), Mitochondrial Function and Pathology (3 papers) and Genetic Neurodegenerative Diseases (3 papers). Thomas Agnew collaborates with scholars based in United Kingdom, Denmark and United States. Thomas Agnew's co-authors include Ivan Ahel, Luca Palazzo, Evgeniia Prokhorova, Andreja Mikoč, Dragana Ahel, Joséphine Groslambert, Michael L. Nielsen, Deeksha Munnur, Marcin J. Suskiewicz and Joanna Poulton and has published in prestigious journals such as Nature Communications, Molecular Cell and Human Molecular Genetics.

In The Last Decade

Thomas Agnew

10 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Agnew United Kingdom	9	218	186	71	43	40	10	335
Danique Beijer United States	9	124 0.6×	75 0.4×	33 0.5×	14 0.3×	22 0.6×	15	231
Bo Pan China	8	201 0.9×	35 0.2×	26 0.4×	4 0.1×	30 0.8×	11	340
Morayo G. Adebiyi United States	8	108 0.5×	87 0.5×	10 0.1×	10 0.2×	11 0.3×	10	334
Jozef P. Bossowski France	7	222 1.0×	28 0.2×	49 0.7×	3 0.1×	14 0.3×	9	363
Riham Abouleisa United States	12	261 1.2×	29 0.2×	15 0.2×	8 0.2×	15 0.4×	24	386
Kimberly Keith United States	5	302 1.4×	50 0.3×	113 1.6×	2 0.0×	20 0.5×	7	438
Jeanne Baker United States	6	240 1.1×	46 0.2×	17 0.2×	5 0.1×	9 0.2×	7	348
Angela To United States	3	107 0.5×	74 0.4×	87 1.2×	2 0.0×	11 0.3×	4	257
Jae Seok Yoon South Korea	11	405 1.9×	39 0.2×	28 0.4×	17 0.4×	7 0.2×	13	554
Florence Renaldo France	11	205 0.9×	43 0.2×	69 1.0×	18 0.4×		19	339

Countries citing papers authored by Thomas Agnew

Since Specialization

Citations

This map shows the geographic impact of Thomas Agnew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Agnew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Agnew more than expected).

Fields of papers citing papers by Thomas Agnew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Agnew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Agnew. The network helps show where Thomas Agnew may publish in the future.

Co-authorship network of co-authors of Thomas Agnew

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Agnew. A scholar is included among the top collaborators of Thomas Agnew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Agnew. Thomas Agnew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Beijer, Danique, Thomas Agnew, J.G.M. Rack, et al.. (2021). Biallelic ADPRHL2 mutations in complex neuropathy affect ADP ribosylation and DNA damage response. Life Science Alliance. 4(11). e202101057–e202101057. 16 indexed citations

2.

Prokhorova, Evgeniia, Thomas Agnew, Anne R. Wondisford, et al.. (2021). Unrestrained poly-ADP-ribosylation provides insights into chromatin regulation and human disease. Molecular Cell. 81(12). 2640–2655.e8. 71 indexed citations

3.

Prokhorova, Evgeniia, Rebecca Smith, Ian Gibbs‐Seymour, et al.. (2021). Serine-linked PARP1 auto-modification controls PARP inhibitor response. Nature Communications. 12(1). 4055–4055. 79 indexed citations

4.

Oliver, Peter L., et al.. (2021). Behavioural Characterisation of Macrod1 and Macrod2 Knockout Mice. Cells. 10(2). 368–368. 11 indexed citations

5.

Agnew, Thomas, Michelle Goldsworthy, Carlos Aguilar, et al.. (2018). A Wars2 Mutant Mouse Model Displays OXPHOS Deficiencies and Activation of Tissue-Specific Stress Response Pathways. Cell Reports. 25(12). 3315–3328.e6. 32 indexed citations

6.

Diot, Alan, Thomas Agnew, Jeremy Sanderson, et al.. (2018). Validating the RedMIT/GFP-LC3 Mouse Model by Studying Mitophagy in Autosomal Dominant Optic Atrophy Due to the OPA1Q285STOP Mutation. Frontiers in Cell and Developmental Biology. 6. 103–103. 9 indexed citations

7.

Agnew, Thomas, et al.. (2018). MacroD1 Is a Promiscuous ADP-Ribosyl Hydrolase Localized to Mitochondria. Frontiers in Microbiology. 9. 20–20. 45 indexed citations

8.

Corrochano, Silvia, Gonzalo Blanco, Debbie Williams, et al.. (2018). A genetic modifier suggests that endurance exercise exacerbates Huntington's disease. Human Molecular Genetics. 27(10). 1723–1731. 14 indexed citations

9.

Morovat, Alireza, Gayani Weerasinghe, Victoria Nesbitt, et al.. (2017). Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice. Journal of Clinical Medicine. 6(8). 80–80. 57 indexed citations

10.

Agnew, Thomas. (2001). Care trusts. The urge to merge.. PubMed. 111(5761). 30–1. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact